SlideShare ist ein Scribd-Unternehmen logo
1 von 16
Copyrighted 2013, Compliance
Insight, Inc.
Top 22 Tips:
Writing for FDA Compliance
Troy Fugate
Compliance Insight, Inc.
Investigator, Auditor
Copyrighted 2013, Compliance
Insight, Inc.
This presentation will cover…
• Why we document?
• If we don’t document or document poorly,
what are the consequences.
• Good writing overview
• Report writing tips
Copyrighted 2013, Compliance
Insight, Inc.
Why document?
• It is the law!
– Thou shall document
• 211.192
– “A written record of the investigation
shall be made and shall include the
conclusions and follow-up”
• Guidance “Investigating OOS Test
Results for Pharmaceutical
Production”
Copyrighted 2013, Compliance
Insight, Inc.
Formal Documentation
• The goal is to clearly describe:
– The issue or problem
– The paths taken during the
investigation
– CAPA
– Conclusion
• Prevents errors due to oral
communication
• Prevents errors due to informal
documentation
Copyrighted 2013, Compliance
Insight, Inc.
Poor Documentation
• Examples
– None
– Confusing, unclear, vague
• Consequences
– Release bad product
– Reject good product
– Legal issues
– Reputation
• FDA
• Public
Copyrighted 2013, Compliance
Insight, Inc.
What are you going to document?
• All GMP related operations
– Manufacturing
– Packaging
– Testing
– Etc.
• Investigations
• Complaints
You are going to document
just about everything in
pharmaceutical operations
– especially dealing with
quality!!!!!
Copyrighted 2013, Compliance
Insight, Inc.
The Top 22 Tips…
1. Be clear, concise and timely
2. Clearly summarize the issue
3. Include all pertinent items found during
the investigation
4. Have a conclusion
5. Indicate CAPA
6. Be approved – QA ++++
7. Be communicated to the appropriate
people
If you don’t have a
conclusion, the FDA
will make one for you!
Copyrighted 2013, Compliance
Insight, Inc.
The Top 22 Tips…
8. Not assume anything
– The reader may not know
• The process (or know if very well)
• The product
• The history
8. Use charts, tables, graphs
9. Do Not use slang, jargon
10.Backup findings with evidence, data
11.Do Not exaggerate
Copyrighted 2013, Compliance
Insight, Inc.
The Top 22 Tips…
13.State the scope of the problem or issue
14.Outline the root cause
15.Indicate CAPA
– Systemic approach
13.Flows well
– Paragraphs connected via some form of
thought process
13.Use bullet points as necessary
Copyrighted 2013, Compliance
Insight, Inc.
The Top 22 Tips…
18.List key dates and times
19.Timeline of the investigation
20.Contain copies of reference data
21.Contain copies of CAPA items
– Training
– Purchases
– Employee issues – NO (this is personal)
18.Be all inclusive to the incident
– Don’t stop just because you “think” you found the
problem
Copyrighted 2013, Compliance
Insight, Inc.
How to write
• Place yourself in the background
• Use nouns and verbs
– Minimal use of adjectives and adverbs
• Revise, revise, revise
– Let others not involved with the issue read the
report
– Remember, the next person to read this
report may be the FDA
Copyrighted 2013, Compliance
Insight, Inc.
How to write
• Avoid “local” or technologically advanced
wording
• Do not inject opinion
• Spell out abbreviations
• Be specific
– The product didn’t meet specifications.
– Better: Product Fugatium Bromide, Tablets,
10 mg, did not meet potency specifications of
92 – 102% as dictated in the USP. The
results were as follows:
Copyrighted 2013, Compliance
Insight, Inc.
How to write
• Select a format and stick with it
• Select a report format
– Introduction
– Outline of investigation
– Summary of investigation
– Conclusion
– CAPA
Copyrighted 2013, Compliance
Insight, Inc.
How to write
• Put statements in a positive form
• Use definite, specific language
• Don’t include needless wording or
statements
• Check your data (calculation errors have
resulted in further problems)
Copyrighted 2013, Compliance
Insight, Inc.
How to write
• The next reader will probably be an
auditor
• Begin with the end in mind
– (i.e. What is your goal?)
• Include all areas of the investigation
– Even those that resulted in “no issues noted”
• Indicate results, expected ranges and
specifications (internal, NDA, ANDA, USP)
For More Information or Help…
• Give us a call at:
– 513-860-3512
– www.Compliance-Insight.com
– FDATrainingTeam@compliance-insight.com
– Free consultation by phone
Copyrighted 2013, Compliance
Insight, Inc.

Weitere ähnliche Inhalte

Was ist angesagt?

Good Documentation Practice
Good Documentation PracticeGood Documentation Practice
Good Documentation Practicecr7clark
 
GXP Inspection readiness
GXP Inspection readinessGXP Inspection readiness
GXP Inspection readinessArete-Zoe, LLC
 
Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry GxPProfessional
 
CHAPTER-1 Information Gathering and Administration.pdf
CHAPTER-1 Information Gathering and Administration.pdfCHAPTER-1 Information Gathering and Administration.pdf
CHAPTER-1 Information Gathering and Administration.pdfDr. Dinesh Mehta
 
Presentation for good documentary practices revised shravan
Presentation for good documentary practices revised shravanPresentation for good documentary practices revised shravan
Presentation for good documentary practices revised shravanshravan dubey
 
Good documentation practice
Good documentation practiceGood documentation practice
Good documentation practicevincyrekha
 
Good Laboratory Practices by Dr. A. Amsavel
Good Laboratory Practices  by Dr. A. AmsavelGood Laboratory Practices  by Dr. A. Amsavel
Good Laboratory Practices by Dr. A. AmsavelDr. Amsavel A
 
Good documentation practice
Good documentation practiceGood documentation practice
Good documentation practiceM S K Anwar
 
Glp guidelines in_qc_laboratory_as_per_ich
Glp guidelines in_qc_laboratory_as_per_ichGlp guidelines in_qc_laboratory_as_per_ich
Glp guidelines in_qc_laboratory_as_per_ichAnu Anusha
 
Quality risk management by talha usmani
Quality risk management by talha usmaniQuality risk management by talha usmani
Quality risk management by talha usmanimtalhausmani
 
Data integrity
Data integrityData integrity
Data integrityKiran Kota
 

Was ist angesagt? (20)

Auditing and inspection
Auditing and inspectionAuditing and inspection
Auditing and inspection
 
Good Documentation Practice
Good Documentation PracticeGood Documentation Practice
Good Documentation Practice
 
FDA Inspection
FDA InspectionFDA Inspection
FDA Inspection
 
GXP Inspection readiness
GXP Inspection readinessGXP Inspection readiness
GXP Inspection readiness
 
Fda Inspection
Fda InspectionFda Inspection
Fda Inspection
 
Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry
 
good documentation practice
good documentation practice good documentation practice
good documentation practice
 
CHAPTER-1 Information Gathering and Administration.pdf
CHAPTER-1 Information Gathering and Administration.pdfCHAPTER-1 Information Gathering and Administration.pdf
CHAPTER-1 Information Gathering and Administration.pdf
 
Presentation for good documentary practices revised shravan
Presentation for good documentary practices revised shravanPresentation for good documentary practices revised shravan
Presentation for good documentary practices revised shravan
 
Data Integrity
Data IntegrityData Integrity
Data Integrity
 
Capa system
Capa systemCapa system
Capa system
 
Capa
CapaCapa
Capa
 
Good documentation practice
Good documentation practiceGood documentation practice
Good documentation practice
 
Good Laboratory Practices by Dr. A. Amsavel
Good Laboratory Practices  by Dr. A. AmsavelGood Laboratory Practices  by Dr. A. Amsavel
Good Laboratory Practices by Dr. A. Amsavel
 
Good documentation practice
Good documentation practiceGood documentation practice
Good documentation practice
 
Equipment qualification
Equipment qualificationEquipment qualification
Equipment qualification
 
Data Integrity 101
Data Integrity 101Data Integrity 101
Data Integrity 101
 
Glp guidelines in_qc_laboratory_as_per_ich
Glp guidelines in_qc_laboratory_as_per_ichGlp guidelines in_qc_laboratory_as_per_ich
Glp guidelines in_qc_laboratory_as_per_ich
 
Quality risk management by talha usmani
Quality risk management by talha usmaniQuality risk management by talha usmani
Quality risk management by talha usmani
 
Data integrity
Data integrityData integrity
Data integrity
 

Ähnlich wie Top 22 Tips: Writing For FDA Compliance

REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENTREGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENTMichael Swit
 
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENTREGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENTMichael Swit
 
Drug Development in Today's Regulatory Environment
Drug Development in Today's Regulatory EnvironmentDrug Development in Today's Regulatory Environment
Drug Development in Today's Regulatory EnvironmentMichael Swit
 
Best Audit Practices: The Top 10 Auditing Mistakes Companies Make
Best Audit Practices: The Top 10 Auditing Mistakes Companies MakeBest Audit Practices: The Top 10 Auditing Mistakes Companies Make
Best Audit Practices: The Top 10 Auditing Mistakes Companies MakeSafetyChain Software
 
Business Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docxBusiness Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docxfelicidaddinwoodie
 
Business Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docxBusiness Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docxhumphrieskalyn
 
Ensuring FDA Regulatory Success for Biomedical Companies
Ensuring FDA Regulatory Success for Biomedical CompaniesEnsuring FDA Regulatory Success for Biomedical Companies
Ensuring FDA Regulatory Success for Biomedical CompaniesMichael Swit
 
Lecture 8 Resources and Costs.pptx
Lecture 8 Resources and Costs.pptxLecture 8 Resources and Costs.pptx
Lecture 8 Resources and Costs.pptxGelmelinaLeaLepitenH
 
Testing & Optimization - A Deeper Look
Testing & Optimization - A Deeper LookTesting & Optimization - A Deeper Look
Testing & Optimization - A Deeper LookCaleb Whitmore
 
5 Proven Strategies For a Successful Analytics Product Launch
5 Proven Strategies For a Successful Analytics Product Launch5 Proven Strategies For a Successful Analytics Product Launch
5 Proven Strategies For a Successful Analytics Product LaunchGoodData
 
Testing the unknown: the art and science of working with hypothesis
Testing the unknown: the art and science of working with hypothesisTesting the unknown: the art and science of working with hypothesis
Testing the unknown: the art and science of working with hypothesisArdita Karaj
 
Regulatory Considerations in Product Development
Regulatory Considerations in Product DevelopmentRegulatory Considerations in Product Development
Regulatory Considerations in Product DevelopmentMichael Swit
 
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...April Bright
 
, please see the feedback within your paper and in the scoring rub.docx
, please see the feedback within your paper and in the scoring rub.docx, please see the feedback within your paper and in the scoring rub.docx
, please see the feedback within your paper and in the scoring rub.docxmadlynplamondon
 
Exaudio, llc Background + MR capabilities
Exaudio, llc Background + MR capabilitiesExaudio, llc Background + MR capabilities
Exaudio, llc Background + MR capabilitiesExaudio
 

Ähnlich wie Top 22 Tips: Writing For FDA Compliance (20)

REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENTREGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
 
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENTREGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
 
Drug Development in Today's Regulatory Environment
Drug Development in Today's Regulatory EnvironmentDrug Development in Today's Regulatory Environment
Drug Development in Today's Regulatory Environment
 
Best Audit Practices: The Top 10 Auditing Mistakes Companies Make
Best Audit Practices: The Top 10 Auditing Mistakes Companies MakeBest Audit Practices: The Top 10 Auditing Mistakes Companies Make
Best Audit Practices: The Top 10 Auditing Mistakes Companies Make
 
ch01.ppt
ch01.pptch01.ppt
ch01.ppt
 
Pai
PaiPai
Pai
 
Quality audit plan
Quality audit planQuality audit plan
Quality audit plan
 
Business Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docxBusiness Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docx
 
Business Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docxBusiness Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docx
 
Mike Roe Creating Client Value
Mike Roe Creating Client ValueMike Roe Creating Client Value
Mike Roe Creating Client Value
 
Ensuring FDA Regulatory Success for Biomedical Companies
Ensuring FDA Regulatory Success for Biomedical CompaniesEnsuring FDA Regulatory Success for Biomedical Companies
Ensuring FDA Regulatory Success for Biomedical Companies
 
Lecture 8 Resources and Costs.pptx
Lecture 8 Resources and Costs.pptxLecture 8 Resources and Costs.pptx
Lecture 8 Resources and Costs.pptx
 
Documentation: First & Last Exit in GMP
Documentation: First & Last Exit in GMP Documentation: First & Last Exit in GMP
Documentation: First & Last Exit in GMP
 
Testing & Optimization - A Deeper Look
Testing & Optimization - A Deeper LookTesting & Optimization - A Deeper Look
Testing & Optimization - A Deeper Look
 
5 Proven Strategies For a Successful Analytics Product Launch
5 Proven Strategies For a Successful Analytics Product Launch5 Proven Strategies For a Successful Analytics Product Launch
5 Proven Strategies For a Successful Analytics Product Launch
 
Testing the unknown: the art and science of working with hypothesis
Testing the unknown: the art and science of working with hypothesisTesting the unknown: the art and science of working with hypothesis
Testing the unknown: the art and science of working with hypothesis
 
Regulatory Considerations in Product Development
Regulatory Considerations in Product DevelopmentRegulatory Considerations in Product Development
Regulatory Considerations in Product Development
 
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...
 
, please see the feedback within your paper and in the scoring rub.docx
, please see the feedback within your paper and in the scoring rub.docx, please see the feedback within your paper and in the scoring rub.docx
, please see the feedback within your paper and in the scoring rub.docx
 
Exaudio, llc Background + MR capabilities
Exaudio, llc Background + MR capabilitiesExaudio, llc Background + MR capabilities
Exaudio, llc Background + MR capabilities
 

Mehr von Compliance Insight, Inc. (14)

July 2015
July 2015July 2015
July 2015
 
GCP Overview by Compliance Insight, Inc.
GCP Overview by Compliance Insight, Inc.GCP Overview by Compliance Insight, Inc.
GCP Overview by Compliance Insight, Inc.
 
FDA audit series part 5, dealing with the 483 or Warning Letter
FDA audit series   part 5, dealing with the 483 or Warning LetterFDA audit series   part 5, dealing with the 483 or Warning Letter
FDA audit series part 5, dealing with the 483 or Warning Letter
 
FDA audit series part 4, the closeout
FDA audit series   part 4, the closeoutFDA audit series   part 4, the closeout
FDA audit series part 4, the closeout
 
Fda audit series part 3, while the fda is there
Fda audit series   part 3, while the fda is  thereFda audit series   part 3, while the fda is  there
Fda audit series part 3, while the fda is there
 
FDA audit series part 2, what to do when the FDA arrives
FDA audit series   part 2, what to do when the FDA arrivesFDA audit series   part 2, what to do when the FDA arrives
FDA audit series part 2, what to do when the FDA arrives
 
FDA audit series part 1, Preparing for the Audit
FDA audit series   part 1, Preparing for the AuditFDA audit series   part 1, Preparing for the Audit
FDA audit series part 1, Preparing for the Audit
 
About Compliance Insight Inc.
About Compliance Insight Inc.About Compliance Insight Inc.
About Compliance Insight Inc.
 
FDA 483 observations in the lab
FDA 483 observations in the labFDA 483 observations in the lab
FDA 483 observations in the lab
 
Basics of FDA GMP Training
Basics of FDA GMP TrainingBasics of FDA GMP Training
Basics of FDA GMP Training
 
FDA GMP Training - The Quality Audit
FDA GMP Training - The Quality AuditFDA GMP Training - The Quality Audit
FDA GMP Training - The Quality Audit
 
21 cfr, parts 210 211
21 cfr, parts 210 21121 cfr, parts 210 211
21 cfr, parts 210 211
 
FDA Warning Letter
FDA Warning LetterFDA Warning Letter
FDA Warning Letter
 
FDA 483
FDA 483FDA 483
FDA 483
 

Kürzlich hochgeladen

The Path to Product Excellence: Avoiding Common Pitfalls and Enhancing Commun...
The Path to Product Excellence: Avoiding Common Pitfalls and Enhancing Commun...The Path to Product Excellence: Avoiding Common Pitfalls and Enhancing Commun...
The Path to Product Excellence: Avoiding Common Pitfalls and Enhancing Commun...Aggregage
 
7.pdf This presentation captures many uses and the significance of the number...
7.pdf This presentation captures many uses and the significance of the number...7.pdf This presentation captures many uses and the significance of the number...
7.pdf This presentation captures many uses and the significance of the number...Paul Menig
 
Call Girls In Panjim North Goa 9971646499 Genuine Service
Call Girls In Panjim North Goa 9971646499 Genuine ServiceCall Girls In Panjim North Goa 9971646499 Genuine Service
Call Girls In Panjim North Goa 9971646499 Genuine Serviceritikaroy0888
 
Boost the utilization of your HCL environment by reevaluating use cases and f...
Boost the utilization of your HCL environment by reevaluating use cases and f...Boost the utilization of your HCL environment by reevaluating use cases and f...
Boost the utilization of your HCL environment by reevaluating use cases and f...Roland Driesen
 
Monthly Social Media Update April 2024 pptx.pptx
Monthly Social Media Update April 2024 pptx.pptxMonthly Social Media Update April 2024 pptx.pptx
Monthly Social Media Update April 2024 pptx.pptxAndy Lambert
 
Yaroslav Rozhankivskyy: Три складові і три передумови максимальної продуктивн...
Yaroslav Rozhankivskyy: Три складові і три передумови максимальної продуктивн...Yaroslav Rozhankivskyy: Три складові і три передумови максимальної продуктивн...
Yaroslav Rozhankivskyy: Три складові і три передумови максимальної продуктивн...Lviv Startup Club
 
FULL ENJOY Call Girls In Majnu Ka Tilla, Delhi Contact Us 8377877756
FULL ENJOY Call Girls In Majnu Ka Tilla, Delhi Contact Us 8377877756FULL ENJOY Call Girls In Majnu Ka Tilla, Delhi Contact Us 8377877756
FULL ENJOY Call Girls In Majnu Ka Tilla, Delhi Contact Us 8377877756dollysharma2066
 
Dr. Admir Softic_ presentation_Green Club_ENG.pdf
Dr. Admir Softic_ presentation_Green Club_ENG.pdfDr. Admir Softic_ presentation_Green Club_ENG.pdf
Dr. Admir Softic_ presentation_Green Club_ENG.pdfAdmir Softic
 
Pharma Works Profile of Karan Communications
Pharma Works Profile of Karan CommunicationsPharma Works Profile of Karan Communications
Pharma Works Profile of Karan Communicationskarancommunications
 
HONOR Veterans Event Keynote by Michael Hawkins
HONOR Veterans Event Keynote by Michael HawkinsHONOR Veterans Event Keynote by Michael Hawkins
HONOR Veterans Event Keynote by Michael HawkinsMichael W. Hawkins
 
FULL ENJOY Call Girls In Mahipalpur Delhi Contact Us 8377877756
FULL ENJOY Call Girls In Mahipalpur Delhi Contact Us 8377877756FULL ENJOY Call Girls In Mahipalpur Delhi Contact Us 8377877756
FULL ENJOY Call Girls In Mahipalpur Delhi Contact Us 8377877756dollysharma2066
 
Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...
Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...
Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...Dave Litwiller
 
Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...
Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...
Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...amitlee9823
 
Organizational Transformation Lead with Culture
Organizational Transformation Lead with CultureOrganizational Transformation Lead with Culture
Organizational Transformation Lead with CultureSeta Wicaksana
 
👉Chandigarh Call Girls 👉9878799926👉Just Call👉Chandigarh Call Girl In Chandiga...
👉Chandigarh Call Girls 👉9878799926👉Just Call👉Chandigarh Call Girl In Chandiga...👉Chandigarh Call Girls 👉9878799926👉Just Call👉Chandigarh Call Girl In Chandiga...
👉Chandigarh Call Girls 👉9878799926👉Just Call👉Chandigarh Call Girl In Chandiga...rajveerescorts2022
 
KYC-Verified Accounts: Helping Companies Handle Challenging Regulatory Enviro...
KYC-Verified Accounts: Helping Companies Handle Challenging Regulatory Enviro...KYC-Verified Accounts: Helping Companies Handle Challenging Regulatory Enviro...
KYC-Verified Accounts: Helping Companies Handle Challenging Regulatory Enviro...Any kyc Account
 
John Halpern sued for sexual assault.pdf
John Halpern sued for sexual assault.pdfJohn Halpern sued for sexual assault.pdf
John Halpern sued for sexual assault.pdfAmzadHosen3
 
RSA Conference Exhibitor List 2024 - Exhibitors Data
RSA Conference Exhibitor List 2024 - Exhibitors DataRSA Conference Exhibitor List 2024 - Exhibitors Data
RSA Conference Exhibitor List 2024 - Exhibitors DataExhibitors Data
 

Kürzlich hochgeladen (20)

The Path to Product Excellence: Avoiding Common Pitfalls and Enhancing Commun...
The Path to Product Excellence: Avoiding Common Pitfalls and Enhancing Commun...The Path to Product Excellence: Avoiding Common Pitfalls and Enhancing Commun...
The Path to Product Excellence: Avoiding Common Pitfalls and Enhancing Commun...
 
7.pdf This presentation captures many uses and the significance of the number...
7.pdf This presentation captures many uses and the significance of the number...7.pdf This presentation captures many uses and the significance of the number...
7.pdf This presentation captures many uses and the significance of the number...
 
Call Girls In Panjim North Goa 9971646499 Genuine Service
Call Girls In Panjim North Goa 9971646499 Genuine ServiceCall Girls In Panjim North Goa 9971646499 Genuine Service
Call Girls In Panjim North Goa 9971646499 Genuine Service
 
Boost the utilization of your HCL environment by reevaluating use cases and f...
Boost the utilization of your HCL environment by reevaluating use cases and f...Boost the utilization of your HCL environment by reevaluating use cases and f...
Boost the utilization of your HCL environment by reevaluating use cases and f...
 
Monthly Social Media Update April 2024 pptx.pptx
Monthly Social Media Update April 2024 pptx.pptxMonthly Social Media Update April 2024 pptx.pptx
Monthly Social Media Update April 2024 pptx.pptx
 
Yaroslav Rozhankivskyy: Три складові і три передумови максимальної продуктивн...
Yaroslav Rozhankivskyy: Три складові і три передумови максимальної продуктивн...Yaroslav Rozhankivskyy: Три складові і три передумови максимальної продуктивн...
Yaroslav Rozhankivskyy: Три складові і три передумови максимальної продуктивн...
 
FULL ENJOY Call Girls In Majnu Ka Tilla, Delhi Contact Us 8377877756
FULL ENJOY Call Girls In Majnu Ka Tilla, Delhi Contact Us 8377877756FULL ENJOY Call Girls In Majnu Ka Tilla, Delhi Contact Us 8377877756
FULL ENJOY Call Girls In Majnu Ka Tilla, Delhi Contact Us 8377877756
 
Dr. Admir Softic_ presentation_Green Club_ENG.pdf
Dr. Admir Softic_ presentation_Green Club_ENG.pdfDr. Admir Softic_ presentation_Green Club_ENG.pdf
Dr. Admir Softic_ presentation_Green Club_ENG.pdf
 
Pharma Works Profile of Karan Communications
Pharma Works Profile of Karan CommunicationsPharma Works Profile of Karan Communications
Pharma Works Profile of Karan Communications
 
HONOR Veterans Event Keynote by Michael Hawkins
HONOR Veterans Event Keynote by Michael HawkinsHONOR Veterans Event Keynote by Michael Hawkins
HONOR Veterans Event Keynote by Michael Hawkins
 
FULL ENJOY Call Girls In Mahipalpur Delhi Contact Us 8377877756
FULL ENJOY Call Girls In Mahipalpur Delhi Contact Us 8377877756FULL ENJOY Call Girls In Mahipalpur Delhi Contact Us 8377877756
FULL ENJOY Call Girls In Mahipalpur Delhi Contact Us 8377877756
 
Mifty kit IN Salmiya (+918133066128) Abortion pills IN Salmiyah Cytotec pills
Mifty kit IN Salmiya (+918133066128) Abortion pills IN Salmiyah Cytotec pillsMifty kit IN Salmiya (+918133066128) Abortion pills IN Salmiyah Cytotec pills
Mifty kit IN Salmiya (+918133066128) Abortion pills IN Salmiyah Cytotec pills
 
Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...
Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...
Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...
 
Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...
Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...
Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...
 
Organizational Transformation Lead with Culture
Organizational Transformation Lead with CultureOrganizational Transformation Lead with Culture
Organizational Transformation Lead with Culture
 
👉Chandigarh Call Girls 👉9878799926👉Just Call👉Chandigarh Call Girl In Chandiga...
👉Chandigarh Call Girls 👉9878799926👉Just Call👉Chandigarh Call Girl In Chandiga...👉Chandigarh Call Girls 👉9878799926👉Just Call👉Chandigarh Call Girl In Chandiga...
👉Chandigarh Call Girls 👉9878799926👉Just Call👉Chandigarh Call Girl In Chandiga...
 
Forklift Operations: Safety through Cartoons
Forklift Operations: Safety through CartoonsForklift Operations: Safety through Cartoons
Forklift Operations: Safety through Cartoons
 
KYC-Verified Accounts: Helping Companies Handle Challenging Regulatory Enviro...
KYC-Verified Accounts: Helping Companies Handle Challenging Regulatory Enviro...KYC-Verified Accounts: Helping Companies Handle Challenging Regulatory Enviro...
KYC-Verified Accounts: Helping Companies Handle Challenging Regulatory Enviro...
 
John Halpern sued for sexual assault.pdf
John Halpern sued for sexual assault.pdfJohn Halpern sued for sexual assault.pdf
John Halpern sued for sexual assault.pdf
 
RSA Conference Exhibitor List 2024 - Exhibitors Data
RSA Conference Exhibitor List 2024 - Exhibitors DataRSA Conference Exhibitor List 2024 - Exhibitors Data
RSA Conference Exhibitor List 2024 - Exhibitors Data
 

Top 22 Tips: Writing For FDA Compliance

  • 1. Copyrighted 2013, Compliance Insight, Inc. Top 22 Tips: Writing for FDA Compliance Troy Fugate Compliance Insight, Inc. Investigator, Auditor
  • 2. Copyrighted 2013, Compliance Insight, Inc. This presentation will cover… • Why we document? • If we don’t document or document poorly, what are the consequences. • Good writing overview • Report writing tips
  • 3. Copyrighted 2013, Compliance Insight, Inc. Why document? • It is the law! – Thou shall document • 211.192 – “A written record of the investigation shall be made and shall include the conclusions and follow-up” • Guidance “Investigating OOS Test Results for Pharmaceutical Production”
  • 4. Copyrighted 2013, Compliance Insight, Inc. Formal Documentation • The goal is to clearly describe: – The issue or problem – The paths taken during the investigation – CAPA – Conclusion • Prevents errors due to oral communication • Prevents errors due to informal documentation
  • 5. Copyrighted 2013, Compliance Insight, Inc. Poor Documentation • Examples – None – Confusing, unclear, vague • Consequences – Release bad product – Reject good product – Legal issues – Reputation • FDA • Public
  • 6. Copyrighted 2013, Compliance Insight, Inc. What are you going to document? • All GMP related operations – Manufacturing – Packaging – Testing – Etc. • Investigations • Complaints You are going to document just about everything in pharmaceutical operations – especially dealing with quality!!!!!
  • 7. Copyrighted 2013, Compliance Insight, Inc. The Top 22 Tips… 1. Be clear, concise and timely 2. Clearly summarize the issue 3. Include all pertinent items found during the investigation 4. Have a conclusion 5. Indicate CAPA 6. Be approved – QA ++++ 7. Be communicated to the appropriate people If you don’t have a conclusion, the FDA will make one for you!
  • 8. Copyrighted 2013, Compliance Insight, Inc. The Top 22 Tips… 8. Not assume anything – The reader may not know • The process (or know if very well) • The product • The history 8. Use charts, tables, graphs 9. Do Not use slang, jargon 10.Backup findings with evidence, data 11.Do Not exaggerate
  • 9. Copyrighted 2013, Compliance Insight, Inc. The Top 22 Tips… 13.State the scope of the problem or issue 14.Outline the root cause 15.Indicate CAPA – Systemic approach 13.Flows well – Paragraphs connected via some form of thought process 13.Use bullet points as necessary
  • 10. Copyrighted 2013, Compliance Insight, Inc. The Top 22 Tips… 18.List key dates and times 19.Timeline of the investigation 20.Contain copies of reference data 21.Contain copies of CAPA items – Training – Purchases – Employee issues – NO (this is personal) 18.Be all inclusive to the incident – Don’t stop just because you “think” you found the problem
  • 11. Copyrighted 2013, Compliance Insight, Inc. How to write • Place yourself in the background • Use nouns and verbs – Minimal use of adjectives and adverbs • Revise, revise, revise – Let others not involved with the issue read the report – Remember, the next person to read this report may be the FDA
  • 12. Copyrighted 2013, Compliance Insight, Inc. How to write • Avoid “local” or technologically advanced wording • Do not inject opinion • Spell out abbreviations • Be specific – The product didn’t meet specifications. – Better: Product Fugatium Bromide, Tablets, 10 mg, did not meet potency specifications of 92 – 102% as dictated in the USP. The results were as follows:
  • 13. Copyrighted 2013, Compliance Insight, Inc. How to write • Select a format and stick with it • Select a report format – Introduction – Outline of investigation – Summary of investigation – Conclusion – CAPA
  • 14. Copyrighted 2013, Compliance Insight, Inc. How to write • Put statements in a positive form • Use definite, specific language • Don’t include needless wording or statements • Check your data (calculation errors have resulted in further problems)
  • 15. Copyrighted 2013, Compliance Insight, Inc. How to write • The next reader will probably be an auditor • Begin with the end in mind – (i.e. What is your goal?) • Include all areas of the investigation – Even those that resulted in “no issues noted” • Indicate results, expected ranges and specifications (internal, NDA, ANDA, USP)
  • 16. For More Information or Help… • Give us a call at: – 513-860-3512 – www.Compliance-Insight.com – FDATrainingTeam@compliance-insight.com – Free consultation by phone Copyrighted 2013, Compliance Insight, Inc.